HiF-Seq™ platform enables high efficiency single cell sequencing and is particularly well-suited for frozen tissue sections from post-mortem brain tissue which have been challenging for conventional single cell sequencing technologies.
Using this proprietary technology, we are creating the world’s largest repository of data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s. With this approach, we can study genomic information for individual cells.
In parallel, we are developing automation systems for sample processing, including sample and library preparation for single cell sequencing which provides scalability at high accuracy and low cost.
As the repository of data derived from the HiF-snRNAseq™ platform continues to grow, it will be increasingly valuable for guiding development of diagnostic assays and therapeutics. We have already discovered a significant list of novel biomarkers and therapeutic targets.
Elucidating critical disease pathways, biomarkers and targets with unprecedented resolution to inform development of new therapeutics and diagnostics.
HiF-Seq™ Platform
Analysis